<- Go Home
Tetra Bio-Pharma Inc.
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada.
Market Cap
$737.00
Volume
177.9K
Cash and Equivalents
$483.2K
EBITDA
-$12.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$0.00
52 Week Low
$0.00
Dividend
N/A
Price / Book Value
-0.00
Price / Earnings
-0.00
Price / Tangible Book Value
-0.00
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$12.3M
Return on Equity
315.85%
Return on Assets
-38.52
Cash and Short Term Investments
$483.2K
Debt
$1.7M
Equity
-$5.9M
Revenue
N/A
Unlevered FCF
-$3.2M
Sector
Pharmaceuticals
Category
N/A